Keywords: Tumors (Post-Treatment), Hyperpolarized MR (Non-Gas)
Motivation: Despite aggressive treatments, patients with GBM have a median overall survival of 14-16 months and a need for noninvasive evaluation of therapeutics is apparent.
Goal(s): To assess whether treatment-induced metabolic changes can be observed in patients using parameters derived from hyperpolarized 13C metabolic imaging data.
Approach: 19 patients with recurrent GBM were followed for at least 6 months following treatment initiation and evaluated at various timepoints using HP-13C imaging.
Results: A difference in trends following treatment was observed in pyruvate-to-lactate conversion for patients who received anti-angiogenic treatments as compared to those who received a protein kinase inhibitor.
Impact: Given the challenges associated with evaluating progression and response to therapy in patients with glioblastoma using conventional MRI, this study provided evidence that hyperpolarized carbon-13 techniques can detect serial changes in dynamic metabolism which might help predict disease status.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords